In this issue:
Ultra-processed food intake and IBD risk
Treatment persistence with ustekinumab/vedolizumab in CD/UC
Salvage tofacitinib for refractory severe UC
Paternal immunosuppressant/ biologic exposure and birth outcomes
High-dose vitamin D did not prevent postoperative CD recurrence
Real-world safety of tofacitinib for UC
Pouchitis and related complications in UC
Predicting colectomy risk after admission for acute severe UC
Reducing tofacitinib dosage for UC in stable remission
Health outcomes for children born to mothers with IBD
Please login below to download this issue (PDF)